Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes - Wikidata - awgldk - TriplyDB

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

http://www.wikidata.org/entity/Q24628948

about

Teneligliptin in management of type 2 diabetes mellitus Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Recent progress in natural products as DPP-4 inhibitors.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.Teneligliptin: a review in type 2 diabetes.Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.Efficacy and safety of teneligliptin.Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study.Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Estimation of Anti Diabetic Teneligliptin in Bulk and Formulation by Densitometric and Spectrophotometric Method

P2860

Q26738356-97C52ABF-4465-4405-9206-CD969FD2351A Q26785454-CB64E83A-0CA3-401F-A62D-422353B063C8 Q33688333-D0E47233-6945-46AD-9499-48845DD3040F Q33835558-3D6F0D22-50A2-4D17-92A7-ED999EC95A8E Q34990233-15645EF0-4F0C-4D13-A865-C758D1B37CFB Q36131466-A12B74C0-231C-4479-8009-756D95355443 Q38205588-721EEC78-D4B9-4844-9F3E-9F8FF6D598D8 Q38524167-14A504B4-854B-4DD5-86CB-E01655682BF6 Q38546981-99AA4DCF-6D13-4ED8-A151-45D06F851270 Q38609598-12143858-DD21-41F8-A432-B7148F07E92A Q40294653-CBC09819-94FB-46D4-90FC-DCDCB6D902F4 Q42330154-5E65BC38-02DB-4511-A565-D64E0114CDE3 Q46231385-07230636-4A4D-4A4D-A351-5220EF73B7BC Q51245374-369267C3-95B7-4BB4-9846-A6B820ADD879 Q51282580-5FBB84E6-2318-4FD2-9735-1F0DCD7B7C2B Q54603928-A6E2CB23-0F62-40DE-915E-BC257268C838 Q55340870-EFDA85AB-9A50-478B-8C50-9C2EB91DA78D Q58268610-60065B20-84BE-4A6B-B94B-F39329E0AE5A

P2860

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

http://www.wikidata.org/entity/Q24628948

description

2013 nî lūn-bûn

@nan

2013 թուականին հրատարակուած գիտական յօդուած

@hyw

2013 թվականին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@ast

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@en

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@nl

type

label

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@ast

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@en

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@nl

prefLabel

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@ast

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@en

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@nl

P1433

Q24628948-FB0B5777-A6BD-4108-AA59-58D1D38065ED

P1476

Q24628948-5096753E-DCA9-4E8F-8333-319A7286738D

P2093

Q24628948-6662CAA8-BDB1-4A60-A7B7-BB64E25E104D

P2860

Q24628948-00513165-8867-48F7-8921-F1EBC8B101CF

Q24628948-04052826-DFD2-45F0-9EF7-C51B28A2ECAB

Q24628948-04BE028B-46F7-43C1-8854-4806F4A59772

Q24628948-099B4B4C-E906-4433-AD11-FEE0A8F82923

Q24628948-0EFF6E26-56B0-4A2F-AFD2-3F5260091EC7

Q24628948-162BF60E-3CF8-45A1-A2E1-F5F87AD9BE3F

Q24628948-1BF6BA09-9537-4771-AF40-4BB9FF4F833C

Q24628948-22E47070-5FC4-4CCF-81AC-C33FBA5B076D

Q24628948-2374029A-677A-4CF3-B78C-67388D75E3B5

Q24628948-27623B88-0369-4E16-9791-7DA142A9F8C8

P304

Q24628948-0D37120D-492E-436F-8799-315AF2A15C24

P31

Q24628948-50235F74-5C37-4E76-A686-2503D9624B96

P3181

Q24628948-DCED8806-CD31-4D69-9DEA-04DBBB166BF3

P356

Q24628948-8E0DA110-C64F-471D-93C1-D7463CC0A22C

P407

Q24628948-FB0A037A-21F1-44A6-A46B-F1E74A7878BD

P478

Q24628948-F4E326FB-6EEE-45F4-9D94-08EBC6B7FBC2

P577

Q24628948-C22667BE-43B7-4D68-92A4-FDCC7A70B216

P698

Q24628948-B91492CA-D6B6-422A-830F-27A17B88FC6F

P921

Q24628948-6DBA5430-457A-4C6F-97C7-DBD3DB88376D

P932

Q24628948-9B73415A-72B9-4AB3-8B27-C5ED646D3B10

P3181

P356

P1433

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

P1476

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

@en

P2093

Miyako Kishimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

The Physiology of Glucagon-like Peptide 1

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.

GIP and GLP-1, the two incretin hormones: Similarities and differences

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

DPP-4 inhibitors and lipids: systematic review and meta-analysis.

Transection of the oesophagus for bleeding oesophageal varices.

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

P304

187-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2355921

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/DMSO.S35682

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23671395

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3650886

http://www.w3.org/2001/XMLSchema#string